542 related articles for article (PubMed ID: 34166502)
21. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
[TBL] [Abstract][Full Text] [Related]
23. Neurological adverse events following CAR T-cell therapy: a real-world analysis.
Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA
Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566
[No Abstract] [Full Text] [Related]
24. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
25. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
[TBL] [Abstract][Full Text] [Related]
26. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.
Wudhikarn K; Bansal R; Khurana A; Hathcock MA; Braksick SA; Bennani NN; Paludo J; Villasboas JC; Wang Y; Johnston PB; Ansell SM; Lin Y
Am J Hematol; 2021 Nov; 96(11):E427-E430. PubMed ID: 34424554
[No Abstract] [Full Text] [Related]
27. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P
Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532
[TBL] [Abstract][Full Text] [Related]
28. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis.
Wood AC; Perez AP; Arciola B; Patel K; Johnson G; DiMaggio E; Bachmeier CA; Reid K; Carallo S; Vargas MH; Faramand R; Chavez JC; Shah B; Gaballa S; Khimani F; Elmariah H; Nishihori T; Lazaryan A; Freeman C; Davila ML; Locke FL; Mhaskar R; Bassil C; Jain MD
Transplant Cell Ther; 2022 Dec; 28(12):829.e1-829.e8. PubMed ID: 36174934
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma.
Dickinson M; Martinez-Lopez J; Jousseaume E; Yang H; Chai X; Xiang C; Wang T; Zhang J; Ramos R; Schuster SJ; Fowler N
Leuk Lymphoma; 2024 Mar; 65(3):323-332. PubMed ID: 38179688
[TBL] [Abstract][Full Text] [Related]
31. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
32. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA; Martus P; Schmitt M; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner-Drouet EM; Wulf GG; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Fante MA; Schroers R; Bayir L; Borchmann P; Buecklein V; Hasenkamp J; Hanoun C; Thomas S; Beelen DW; Lengerke C; Kroeger N; Dreger P
Blood; 2022 Jul; 140(4):349-358. PubMed ID: 35316325
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
34. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
[TBL] [Abstract][Full Text] [Related]
35. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
[TBL] [Abstract][Full Text] [Related]
36. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Sim AJ; Jain MD; Figura NB; Chavez JC; Shah BD; Khimani F; Lazaryan A; Krivenko G; Davila ML; Liu HD; Falchook AD; Dahiya S; Rapoport AP; Kim S; Locke FL; Robinson TJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1012-1021. PubMed ID: 31175906
[TBL] [Abstract][Full Text] [Related]
37. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.
Wudhikarn K; Bansal R; Khurana A; Hathcock MA; Bennani NN; Paludo J; Villasboas JC; Wang Y; Johnston PB; Ansell SM; Lin Y
Blood Cancer J; 2021 Jul; 11(7):124. PubMed ID: 34210955
[No Abstract] [Full Text] [Related]
38. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
39. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Rubin DB; Al Jarrah A; Li K; LaRose S; Monk AD; Ali AB; Spendley LN; Nikiforow S; Jacobson C; Vaitkevicius H
JAMA Neurol; 2020 Dec; 77(12):1536-1542. PubMed ID: 32777012
[TBL] [Abstract][Full Text] [Related]
40. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Adv Ther; 2020 Jul; 37(7):3040-3058. PubMed ID: 32524498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]